Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children (Q24203905)

object named as

Peter Doshi

0 references

author name string

Mark A Jones

0 references

Chris B Del Mar

0 references

Carl J Heneghan

0 references

Rokuro Hama

0 references

Matthew J Thompson

Cochrane Database of Systematic Reviews

0 references

publication date

18 January 2012

0 references

published in

0 references

cites work

Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Joining the DoTS: new approach to classifying adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Does This Patient Have Influenza?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Challenges in systematic reviews that assess treatment harms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Complications: tracking down the data on oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Neuraminidase inhibitors—the story behind the Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Safety and pharmacokinetics of oseltamivir at standard and high dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Why don't we have all the evidence on oseltamivir?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Missing clinical trial data: setting the record straight

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Unpublished data can be of value in systematic reviews of adverse effects: methodological overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Developing new antiviral agents for influenza treatment: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Publication bias in clinical trials due to statistical significance or direction of trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Neuraminidase inhibitors for preventing and treating influenza in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Ensuring safe and effective drugs: who can do what it takes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

How useful are unpublished data from the Food and Drug Administration in meta-analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Neuraminidase inhibitors for preventing and treating influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Reporting bias in medical research - a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Roles of neuraminidase in the initial stage of influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Controversies concerning randomization and additivity in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Antivirals for influenza in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Searching for unpublished trials in Cochrane reviews may not be worth the effort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

Vaccines for preventing influenza in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

7 January 2021

In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

7 January 2021

Does oseltamivir really reduce complications of influenza?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

7 January 2021

Opening up data at the European Medicines Agency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

7 January 2021

Does influenza transmission occur from asymptomatic infection or prior to symptom onset?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

7 January 2021

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008965.PUB3

7 January 2021

10.1002/14651858.CD008965.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_xltsf34s4jhwtfz7euybyvuymm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xltsf34s4jhwtfz7euybyvuymm

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22258996

1 reference

Consolidated OpenCitations Corpus – April 2017